<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="359">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466670</url>
  </required_header>
  <id_info>
    <org_study_id>33788820.9.0000.0068</org_study_id>
    <nct_id>NCT04466670</nct_id>
  </id_info>
  <brief_title>Hemostasis in COVID-19: an Adaptive Clinical Trial</brief_title>
  <official_title>Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypercoagulability has been demonstrated in COVID-19, leading to respiratory distress and
      increased mortality. This is adaptive clinical trial to compare effectiveness and safety of
      four therapeutic strategies in hospital mortality in patients with COVID-19: standard
      prophylaxis, therapeutic dose anticoagulation, inhaled UFH associated with standard
      prophylaxis and ASA associated with standard prophylaxis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 8, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital discharge - alive / death</measure>
    <time_frame>30 days</time_frame>
    <description>Number of COVID-19 positive patients who are alive within 30 days of symptoms onset</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of mechanical ventilation free days</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of length of mechanical ventilation free days between each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of renal replacement therapy free days</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of length of renal replacement therapy free days between each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of documented venous thromboembolism or arterial thrombosis</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of number of thrombosis events between each treatment arm.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>phase 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>phase 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>phase 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>phase 2C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>unfractionated Heparin</intervention_name>
    <description>Unfractionated heparin dosed to target anti-Xa level 0.3 - 0.7 IU/mL (if creatinine clearance less than 30ml/min), during at least 5 days AND arterial oxygen saturation greater than or equal to 92% or PaO2 to FiO2 ratio greater than 200 for 2 consecutive days.</description>
    <arm_group_label>phase 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated heparin nebulized</intervention_name>
    <description>unfractionated heparin - 25,000 U/ 5 ml nebulized inhalation every 6 hours during at least 5 days AND arterial oxygen saturation greater than or equal to 92% or PaO2 to FiO2 ratio greater than 200 for 2 consecutive days associated to thromboprophylaxis institutional protocol.</description>
    <arm_group_label>phase 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>Aspirin (ASA) 100 mg daily PO during at least 5 days AND arterial oxygen saturation greater than or equal to 92% or PaO2 to FiO2 ratio greater than 200 for 2 consecutive days associated to thromboprophylaxis institutional protocol.</description>
    <arm_group_label>phase 2C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than or equal to 30ml/min) during at least 5 days AND arterial oxygen saturation greater than or equal to 92% or PaO2 to FiO2 ratio greater than 200 for 2 consecutive days.</description>
    <arm_group_label>phase 2A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult ≥18 years of age at time of enrollment

          -  Subjects with a positive COVID-19 diagnosis by RT-PCR or serologic testing

          -  Subject (or legally authorized representative) must be willing, understanding and able
             to provide written informed consent.

        Exclusion Criteria:

          1. General

               -  Indications for therapeutic anticoagulation

               -  History of chronic lung disease oxygen dependent

               -  Pregnancy

               -  Death considered imminent and inevitable within 24 hours

               -  Patients under exclusive palliative care

               -  Participation in another trial of investigational drug

               -  Body weight &lt; 40 Kg

               -  Total bilirubin &gt; 20 mg/dL

               -  Severe active bleeding

               -  Known allergy to UFH or LMWH

               -  History of heparin-induced thrombocytopenia (HIT) within the past 6 months

               -  Bacterial endocarditis

          2. Exclusion criteria at phase 1

             • Platelets &lt; 25,000

          3. Exclusion criteria at phase 2

               -  Platelets &lt; 50,000

               -  History of surgery in the last 30 days

               -  Intervention C: allergy to ASS and long-term use of antiplatelet drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderson Rocha</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanderson Rocha, MD.PhD</last_name>
      <phone>+55-11-26617575</phone>
      <email>vanderson.rocha@hc.fm.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Yeh-Li Ho, MD.PhD</last_name>
      <phone>+55-11-26616045</phone>
      <email>ho.yeh@hc.fm.usp.br</email>
    </contact_backup>
    <investigator>
      <last_name>Yeh-Li Ho, MD.PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elbio A D'Amico, MD.PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula R Villaca, MD.PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Rotschild, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erica Okazaki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tania RF Rocha, MPharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4.</citation>
    <PMID>15842354</PMID>
  </reference>
  <results_reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </results_reference>
  <results_reference>
    <citation>Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, Li P, Zhou Y, Lin YF, Duan Q, Luo G, Fan S, Lu Y, Feng A, Zhan Y, Liang B, Cai W, Zhang L, Du X, Li L, Shu Y, Zou H. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020 Jun;80(6):656-665. doi: 10.1016/j.jinf.2020.03.041. Epub 2020 Apr 10.</citation>
    <PMID>32283155</PMID>
  </results_reference>
  <results_reference>
    <citation>Arachchillage DRJ, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 May;18(5):1233-1234. doi: 10.1111/jth.14820.</citation>
    <PMID>32291954</PMID>
  </results_reference>
  <results_reference>
    <citation>Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020 Apr;18(4):786-787. doi: 10.1111/jth.14781. Epub 2020 Mar 24.</citation>
    <PMID>32212240</PMID>
  </results_reference>
  <results_reference>
    <citation>Lippi G, Favaloro EJ. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis. Thromb Haemost. 2020 May;120(5):876-878. doi: 10.1055/s-0040-1709650. Epub 2020 Apr 3.</citation>
    <PMID>32246450</PMID>
  </results_reference>
  <results_reference>
    <citation>Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388. doi: 10.1164/rccm.202002-0445OC.</citation>
    <PMID>32275452</PMID>
  </results_reference>
  <results_reference>
    <citation>Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020 Jun;18(6):1421-1424. doi: 10.1111/jth.14830. Epub 2020 May 6.</citation>
    <PMID>32271988</PMID>
  </results_reference>
  <results_reference>
    <citation>Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.</citation>
    <PMID>32291094</PMID>
  </results_reference>
  <results_reference>
    <citation>Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain V, Schneider F, Grunebaum L, Anglés-Cano E, Sattler L, Mertes PM, Meziani F; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x. Epub 2020 May 4.</citation>
    <PMID>32367170</PMID>
  </results_reference>
  <results_reference>
    <citation>Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Alexia B, Sandri MT, Barco S; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020 Jul;191:9-14. doi: 10.1016/j.thromres.2020.04.024. Epub 2020 Apr 23.</citation>
    <PMID>32353746</PMID>
  </results_reference>
  <results_reference>
    <citation>Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, Bouman CCS, Beenen LFM, Kootte RS, Heijmans J, Smits LP, Bonta PI, van Es N. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020 Aug;18(8):1995-2002. doi: 10.1111/jth.14888. Epub 2020 Jul 27.</citation>
    <PMID>32369666</PMID>
  </results_reference>
  <results_reference>
    <citation>Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020 Jul;18(7):1743-1746. doi: 10.1111/jth.14869. Epub 2020 May 27.</citation>
    <PMID>32320517</PMID>
  </results_reference>
  <results_reference>
    <citation>Gralinski LE, Bankhead A 3rd, Jeng S, Menachery VD, Proll S, Belisle SE, Matzke M, Webb-Robertson BJ, Luna ML, Shukla AK, Ferris MT, Bolles M, Chang J, Aicher L, Waters KM, Smith RD, Metz TO, Law GL, Katze MG, McWeeney S, Baric RS. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio. 2013 Aug 6;4(4). pii: e00271-13. doi: 10.1128/mBio.00271-13.</citation>
    <PMID>23919993</PMID>
  </results_reference>
  <results_reference>
    <citation>Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020 Apr 16;181(2):281-292.e6. doi: 10.1016/j.cell.2020.02.058. Epub 2020 Mar 9.</citation>
    <PMID>32155444</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.</citation>
    <PMID>32142651</PMID>
  </results_reference>
  <results_reference>
    <citation>Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004 Jun;203(2):631-7.</citation>
    <PMID>15141377</PMID>
  </results_reference>
  <results_reference>
    <citation>Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.</citation>
    <PMID>32227760</PMID>
  </results_reference>
  <results_reference>
    <citation>Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.</citation>
    <PMID>32437596</PMID>
  </results_reference>
  <results_reference>
    <citation>Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, da Silva LFF, de Oliveira EP, Saldiva PHN, Mauad T, Negri EM. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020 Jun;18(6):1517-1519. doi: 10.1111/jth.14844.</citation>
    <PMID>32294295</PMID>
  </results_reference>
  <results_reference>
    <citation>Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, Pesenti A, Peyvandi F, Tripodi A. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020 Jul;18(7):1738-1742. doi: 10.1111/jth.14850. Epub 2020 Jun 24.</citation>
    <PMID>32302438</PMID>
  </results_reference>
  <results_reference>
    <citation>Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014. Epub 2020 Apr 15.</citation>
    <PMID>32305740</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.</citation>
    <PMID>32192578</PMID>
  </results_reference>
  <results_reference>
    <citation>Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020 Jul;18(7):1548-1555. doi: 10.1111/jth.14872. Epub 2020 Jun 3. Review.</citation>
    <PMID>32329246</PMID>
  </results_reference>
  <results_reference>
    <citation>White D, MacDonald S, Bull T, Hayman M, de Monteverde-Robb R, Sapsford D, Lavinio A, Varley J, Johnston A, Besser M, Thomas W. Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis. 2020 Aug;50(2):287-291. doi: 10.1007/s11239-020-02145-0. Erratum in: J Thromb Thrombolysis. 2020 Jun 22;:.</citation>
    <PMID>32445064</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e24S-e43S. doi: 10.1378/chest.11-2291. Review. Erratum in: Chest. 2012 May;141(5):1369. Dosage error in article text. Chest. 2013 Aug;144(2):721. Dosage error in article text.</citation>
    <PMID>22315264</PMID>
  </results_reference>
  <results_reference>
    <citation>Barrett CD, Moore HB, Yaffe MB, Moore EE. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment. J Thromb Haemost. 2020 Aug;18(8):2060-2063. doi: 10.1111/jth.14860. Epub 2020 Jun 14.</citation>
    <PMID>32302462</PMID>
  </results_reference>
  <results_reference>
    <citation>Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17. Review.</citation>
    <PMID>32311448</PMID>
  </results_reference>
  <results_reference>
    <citation>Maatman TK, Jalali F, Feizpour C, Douglas A 2nd, McGuire SP, Kinnaman G, Hartwell JL, Maatman BT, Kreutz RP, Kapoor R, Rahman O, Zyromski NJ, Meagher AD. Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019. Crit Care Med. 2020 Sep;48(9):e783-e790. doi: 10.1097/CCM.0000000000004466.</citation>
    <PMID>32459672</PMID>
  </results_reference>
  <results_reference>
    <citation>Nahum J, Morichau-Beauchant T, Daviaud F, Echegut P, Fichet J, Maillet JM, Thierry S. Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). JAMA Netw Open. 2020 May 1;3(5):e2010478. doi: 10.1001/jamanetworkopen.2020.10478.</citation>
    <PMID>32469410</PMID>
  </results_reference>
  <results_reference>
    <citation>Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh WK, Naymagon L. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. Blood. 2020 Jul 2;136(1):144-147. doi: 10.1182/blood.2020006941.</citation>
    <PMID>32462179</PMID>
  </results_reference>
  <results_reference>
    <citation>Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S, Nadkarni GN. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020 Jul 7;76(1):122-124. doi: 10.1016/j.jacc.2020.05.001. Epub 2020 May 6.</citation>
    <PMID>32387623</PMID>
  </results_reference>
  <results_reference>
    <citation>Juschten J, Tuinman PR, Juffermans NP, Dixon B, Levi M, Schultz MJ. Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies. Ann Transl Med. 2017 Nov;5(22):444. doi: 10.21037/atm.2017.08.23. Review.</citation>
    <PMID>29264361</PMID>
  </results_reference>
  <results_reference>
    <citation>Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care. 2010;14(5):R180. doi: 10.1186/cc9286. Epub 2010 Oct 11.</citation>
    <PMID>20937093</PMID>
  </results_reference>
  <results_reference>
    <citation>Viecca M, Radovanovic D, Forleo GB, Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacol Res. 2020 Aug;158:104950. doi: 10.1016/j.phrs.2020.104950. Epub 2020 May 23.</citation>
    <PMID>32450344</PMID>
  </results_reference>
  <results_reference>
    <citation>Connor JT, Elm JJ, Broglio KR; ESETT and ADAPT-IT Investigators. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol. 2013 Aug;66(8 Suppl):S130-7. doi: 10.1016/j.jclinepi.2013.02.015.</citation>
    <PMID>23849147</PMID>
  </results_reference>
  <results_reference>
    <citation>Gsponer T, Gerber F, Bornkamp B, Ohlssen D, Vandemeulebroecke M, Schmidli H. A practical guide to Bayesian group sequential designs. Pharm Stat. 2014 Jan-Feb;13(1):71-80. doi: 10.1002/pst.1593. Epub 2013 Aug 24.</citation>
    <PMID>24038922</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Vanderson Geraldo Rocha</investigator_full_name>
    <investigator_title>Full professor</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Coagulopathy</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Respiratory failure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

